Investment analysts at StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Several other research firms have also recently weighed in on AFMD. Wells Fargo & Company lowered their price target on Affimed from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, December 12th. Truist Financial lowered their price target on Affimed from $12.00 to $8.00 in a report on Monday, December 12th. Piper Sandler lowered their price target on Affimed from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, December 12th. HC Wainwright began coverage on Affimed in a report on Monday, December 12th. They set a “buy” rating and a $6.00 price target on the stock. Finally, SVB Leerink lowered their price target on Affimed from $10.00 to $6.00 and set an “outperform” rating on the stock in a report on Monday, December 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Affimed currently has an average rating of “Moderate Buy” and a consensus price target of $5.83.
Affimed Stock Performance
AFMD stock opened at $0.76 on Thursday. The stock has a market capitalization of $93.80 million, a PE ratio of -1.21 and a beta of 2.58. Affimed has a 12-month low of $0.74 and a 12-month high of $5.10. The company has a current ratio of 5.65, a quick ratio of 5.63 and a debt-to-equity ratio of 0.07. The stock’s 50 day simple moving average is $1.04 and its 200 day simple moving average is $1.59.
Hedge Funds Weigh In On Affimed
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.